EHRA Premium Access

Thromboembolic risk in patients with atrial fibrillation and valvular heart disease according to the EHRA Type 2 definition: beyond mitral stenosis and mechanical prosthetic heart valve - Discussion

Topic: Stroke in Atrial Fibrillation

Presentation

About the speaker

Professor Paulus Kirchhof

University Heart & Vascular Center Hamburg, Hamburg (Germany)
43 presentations
0 follower

10 more presentations in this session

Uninterrupted edoxaban versus vitamin k antagonists for ablation of atrial fibrillation:the ELIMINATE-AF Trial

Speaker: Professor S. Hohnloser (Frankfurt, DE)

Thumbnail

ELIMINATE-AF Trial - Discussion

Speaker: Associate Professor T. Potpara (Belgrade, RS)

Thumbnail

Internal vs. external electrical cardioversion of atrial arrhythmias in patients with an implantable cardioverter-defibrillator: a randomised controlled clinical trial

Speaker: Doctor J. Luker (Cologne, DE)

Thumbnail

Internal vs. external electrical cardioversion of atrial arrhythmias in patients with an implantable cardioverter-defibrillator: a randomised controlled clinical trial - Discussion

Speaker: Professor I. Van Gelder (Groningen, NL)

Thumbnail

Thromboembolic risk in patients with atrial fibrillation and valvular heart disease according to the EHRA Type 2 definition: beyond mitral stenosis and mechanical prosthetic heart valve.

Speaker: Miss L. Melgaard (Aalborg, DK)

Thumbnail

Access the full session

Late-breaking trials 3

Speakers: Professor P. Kirchhof, Professor S. Hohnloser, Associate Professor T. Potpara, Doctor J. Luker, Professor I. Van Gelder...
Thumbnail

About the event

Image

EHRA 2019

17 March - 19 March 2019

Sessions Presentations

This platform is supported by

logo Novo Nordisk